This is the second of two posts about Macular Degenerative Disease, from the patient's symptoms to the researchers pursuing the cure.
Advances in science have increased life expectancy in the Western world, yet this progress has come with a cost: the human body is not designed to maintain such a long life. Our population has more elderly members who endure a very low quality of life, suffering from degenerating bodies. As Bette Davis famous quote goes: “Old age ain’t for sissies”. Wouldn’t it be wonderful if we could repair or replace the malfunctioning body components? Design a new body that could keep up with our thirst for life?
Age-related Macular Degenerative Disease (AMD) is the leading cause of blindness in the Western world. According to the Macular Disease Society, only in the UK 250.000 people suffer from AMD. This condition usually affects people over 60, but macular degeneration can also appear at young age.
What Causes AMD?
One of the main causes of AMD is the degeneration and loss of the retinal pigmented epithelium cells (RPE). These RPE cells have several functions:
- keep the retinal layer alive
- get rid of the waste material
- transport water
- act as a barrier preventing blood to enter the retina
- keep photoreceptors alive (cells that respond to light).
- RPE growth is closely linked to the photoreceptors during nervous system development.
The London Project is a research endeavour that aims to restore the damaged RPE cells before it causes complete blindness to the AMD patient. Regenerating damaged tissue is ambitious, but regenerating tissue in the central nervous system is mind blowing.
Schematic of the cellular organization of the retina showing the area where the RPE cells are being replaced
(image from Carr et al. PLoS ONE 2009) |
Three groups coordinate in The London Project: one specialized in developing cells ready for transplant working in the Institute of Ophthalmology, University College London (UCL), a clinical group of surgeons and eye specialists based at Moorfields Eye Hospital and a human embryonic stem cell group in the University of Sheffield’s Centre for Stem Cell Biology.
Dr Amanda Carr, one of the neuroscientists working in the UCL group in The London Project, takes us for a peek inside the lab and tells us about her fascinating work.
“We generate new RPE cells by using either human embryonic stem cells or the patient’s own somatic stem cells”Amanda explains.
“We generate new RPE cells by using either human embryonic stem cells or the patient’s own somatic stem cells”Amanda explains.
"Our project aims to start treating the other eye of the patient with AMD, where RPE cells most probably have started to degenerate too, but the rest of the cells in the retina are still healthy. If we replace the RPE cells in time, before the other cell types in the retina are affected, then the patient will have a functional retina and will not go blind.
Being able to know in advance that a subject’s RPE cells will degenerate offers a chance to start treatment in time to preserve both eyes. If your parents have had AMD there is a chance that you will suffer from it too".
![]() |
| Amanda Carr in a laboratory in the Institute of Opthalmology (University College London) |
"When a patient goes blind in one eye, usually the other eye will degenerate too. Once the first symptoms appear it is usually too late for treatment because it means that not only have the RPE cells have degenerated, the seeing part of the eye, the photoreceptors, have also been affected. We are not able to replace photoreceptors at the moment, although promising research in animals is currently being developed and this might be an option in the future (Pearson et al., 2012)".
HESC have the capacity of being pluripotent (they can differentiate into any type of cell) and unlimited self-renewal. This last capacity of self-renewal makes them cancerous, so when undifferentiated HESC cells should not be used for transplants. Once the cell has differentiated to a certain type of cell, then they remain stable and are safe to use for transplants.
“We work with a group from the University of Sheffield’s Centre for Stem Cell Biology who provides us with the HESC cells. The HESC cells we use were derived in Sheffield over 10 years ago from a single fertilized embryo, which was donated after in vitro fertilization. These cells divide unlimitedly so we have a constant supply of stem cells".
![]() | |||
| Diagram by Amanda Carr explaining the process of generating RPE cells using human embryonic stem cells (HSC). |
Induced pluripotent somatic cells (iPS) are cells originated from adult human tissue, contrary to HESC which can turn into any type of cell, iPS cells can only turn into certain types of cells, they are multipotent.
Amanda explains, “Generating iPS cells is a long process, it takes around 6 months from the extraction of a sample of the patient’s skin to the production of mature RPE cells. In theory, if these cells were to be used as a therapeutic, because these cells are from the own patient, he/she won’t have an immune response to the implant [...]The iPS technology is still under development, it is a plausible treatment for the future, but current implants are using the RPE cells generated from the HESC cells”.
![]() | |||||
|
"Generating iPS cells takes several stages. First, we take a sample of the patient’s skin, which is composed by somatic cells. When the sample is kept under appropriate culture conditions fibroblasts will grow from the biopsy. Fibroblasts are still somatic but will divide to form even more fibroblasts. Using viruses encoding embryonic transcription factors, we can manipulate these fibroblasts. We use four different transcription factors to reprogram the somatic fibroblasts so that they look and behave like pluripotent embryonic stem cells".
![]() |
| Checking samples of iPS cells under the microscope |
"Within a couple of days the reprogrammed fibroblast cells start to look different: they turn from long thin spindly cells, into round cells which grow in packed colonies that expand and get bigger. A sample of these cells is tested to see if it has the capacity to differentiate into different types of cells, if they are pluripotent or not. If successful, the remaining sample in the petri dish - the one we have not allowed to differentiate - will be used as a stem cell line for developing differentiated RPE cells".
Under the microscope the samples of cells are seen as these dots.
On the top left image shows the long spindly fibroblast cells researchers begin with. On the top right image shows differentiated iPS cells, which are disposed in very small cells tightly packed into defined colonies.
The bottom image shows the RPE cell monolayer.
"RPE cells are pigmented, which is really useful for experimenters as they are visually very distinctive. They look dark brown and it is easy to separate them from the rest of the non-pigmented sample".
![]() |
| Samples of iPS cells that are started to differentiate into retinal pigment epithelium (RPE) cells. The dark brown spots in the petri dish are RPE cells. |
As if generating new RPE cells and testing their functionality was not enough, researchers encountered another challenge: RPE cells don’t stick to the membrane that usually supports them in the retina (the Bruchs membrane). The researchers had to develop an artificial membrane, porous enough to let water in, keep the new RPE cells in place and not degenerate inside the eye. Amanda smiles and says “This membrane is as thin as kitchen cling film”.
Amanda argues that because the eye is the only directly observable part of the central nervous system, the implanted stem cells in the eye can be checked easily and non-invasively. This is not the case for the rest of the nervous system.
The clinical group at Moorfields Eye Hospital also set an ambitious goal: what if the restoration of RPE cells in AMD patients could be done as an outpatient procedure? The aim is to develop a procedure as simple as cataract surgery.
The clinical group at Moorfields Eye Hospital also set an ambitious goal: what if the restoration of RPE cells in AMD patients could be done as an outpatient procedure? The aim is to develop a procedure as simple as cataract surgery.
In 2012 the London Project completed the large animal safety study trials using RPE cells originating from HESC cells. Currently the cells are being prepared for Phase I/II clinical trials which are expected to commence in 2013 at Moorfields Eye Hospital in London. The London Project is now using iPS cell technologies to derive RPE cells from patients with various eye diseases. The cells will be used to model disease development and will also provide a new in vitro cell system for drug discovery.
The London Project seems to be ahead of the current pioneering stem cell research - which is starting to successfully recover lost functions in animals, but are not ready for human pilot trials. An example of these works have been recently published in the journal Nature: scientists at the University of Sheffield could partially restore hearing loss in gerbils after stem cell implants in their cochlea (this work was also commented in The Guardian newspaper) and scientists at the University College London, Cornell and Johns Hopkins could restore vision in mice after stem cell implants in the photoreceptors in their retina.
All the advances in regenerative medicine will not make us immortal, yet they can push the boundaries for a better and a longer life, provide a better future for the next generations and make old age suitable for “sissies”. It is science at its best.
I would like to thank Dr Amanda Carr for sharing her work, her constant help and generosity. I would also like to thank Dr Carlos Gias for his helpful comments on this and other articles of the blog.
I would like to thank Dr Amanda Carr for sharing her work, her constant help and generosity. I would also like to thank Dr Carlos Gias for his helpful comments on this and other articles of the blog.
References
Bull ND, Martin KR (2011) Concise Review: Stem Cell-Based Therapies for Retinal Neurodegenerative Diseases. Stem Cells Aug;29(8):1170-5.
Carr AJ, Vugler AA, Hikita ST, Lawrence JM, Gias C, Chen LL, Buchholz DE, Ahmado A, Semo M, Smart MJK, Hasan S, da Cruz L, Johnson LV, Clegg DO, Coffey P (2009) Protective Effects of Human iPS-Derived Retinal Pigment Epithelium Cell Transplantation in the Retinal Dystrophic Rat. PLoS One, Dec 3; 4(12):e8152
Chen W, Jongkamonwiwat N, Abbas L, Eshtan SJ, Johnson SL, Kuhn S, Milo M, Thurlow JK, Andrews PW, Marcotti W, Moore HD, Rivolta MN(2012) Restorationof auditory evoked responses by human ES-cell-derived otic progenitors. Nature Sep 12 doi:10.1038/nature 11415
Pearson RA, Barber AC, Rizzi M, Hippert C, Xue T, West EL, Duran Y, Smith AJ, Chuang JZ, Azam SA, Luhmann UF, Benucci A, Sung CH, Bainbridge JW, Carandini M, Yau KW, Sowden JC, Ali RR. (2012) Restoration of vision after transplantation of photoreceptors. Nature May 3; 485(7396): 99-103.
Strauss O (2005) The Retinal Pigment Epithelium in Visual Function Physiol Rev Jul; 85(3): 845-881
Vugler A, Lawrence J, Walsh J, Carr A, Gias C, Semo M, Ahmado A, Da Cruz L, Andrews P, Coffey P (2007) Embrionic Stem Cells and Retinal Repair Mech Dev Nov-Dec;124(11-12).
Press Articles
"Human stem cells partially restore hearing to deaf gerbils"article by Ian Sample published in the The Guardian newspaper on the 12th of September 2012 .
Carr AJ, Vugler AA, Hikita ST, Lawrence JM, Gias C, Chen LL, Buchholz DE, Ahmado A, Semo M, Smart MJK, Hasan S, da Cruz L, Johnson LV, Clegg DO, Coffey P (2009) Protective Effects of Human iPS-Derived Retinal Pigment Epithelium Cell Transplantation in the Retinal Dystrophic Rat. PLoS One, Dec 3; 4(12):e8152
Chen W, Jongkamonwiwat N, Abbas L, Eshtan SJ, Johnson SL, Kuhn S, Milo M, Thurlow JK, Andrews PW, Marcotti W, Moore HD, Rivolta MN(2012) Restorationof auditory evoked responses by human ES-cell-derived otic progenitors. Nature Sep 12 doi:10.1038/nature 11415
Pearson RA, Barber AC, Rizzi M, Hippert C, Xue T, West EL, Duran Y, Smith AJ, Chuang JZ, Azam SA, Luhmann UF, Benucci A, Sung CH, Bainbridge JW, Carandini M, Yau KW, Sowden JC, Ali RR. (2012) Restoration of vision after transplantation of photoreceptors. Nature May 3; 485(7396): 99-103.
Strauss O (2005) The Retinal Pigment Epithelium in Visual Function Physiol Rev Jul; 85(3): 845-881
Vugler A, Lawrence J, Walsh J, Carr A, Gias C, Semo M, Ahmado A, Da Cruz L, Andrews P, Coffey P (2007) Embrionic Stem Cells and Retinal Repair Mech Dev Nov-Dec;124(11-12).
Press Articles
"Human stem cells partially restore hearing to deaf gerbils"article by Ian Sample published in the The Guardian newspaper on the 12th of September 2012 .

































